BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv. 2004;4:97-107. [PMID: 15087483 DOI: 10.1124/mi.4.2.7] [Cited by in Crossref: 100] [Cited by in F6Publishing: 107] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Faheem SA, Hazem RM, Elsayed NM, Ahmed YM, Saeed NM. Niclosamide modulates cyclosporin A-induced hepatotoxicity in a mouse model: PPAR-γ and Wnt/β-catenin crosstalk. International Immunopharmacology 2023;117:109941. [DOI: 10.1016/j.intimp.2023.109941] [Reference Citation Analysis]
2 Cararo-lopes MM, Souza DG, Ganzella M, Hansel G, Kazlauckas V, De Mello PS, Lima LDS, Kawamoto EM, Portela LV, Souza DO, Scavone C, Böhmer AE. Long-term cyclosporine A treatment promotes anxiety-like behavior: Possible relation with glutamate signaling in rat hippocampus. Journal of Affective Disorders Reports 2022;10:100394. [DOI: 10.1016/j.jadr.2022.100394] [Reference Citation Analysis]
3 Mesripour A, Aghamohseni M. Melatonin prevented depressive-like behavior following cyclosporine A or interferon-α administration in mice. HUJPHARM 2022. [DOI: 10.52794/hujpharm.1061875] [Reference Citation Analysis]
4 Heckelmann J, Weber Y. Einfluss von Medikamenten auf das EEG: Eine Übersicht. Klinische Neurophysiologie 2022;53:148-153. [DOI: 10.1055/a-1875-1645] [Reference Citation Analysis]
5 Shah S, Ginat DT. Calcineurin Inhibitors. Neuroimaging Pharmacopoeia 2022. [DOI: 10.1007/978-3-031-08774-5_22] [Reference Citation Analysis]
6 Liou A, Kline C, Mueller S. Neurologic complications in the treatment of childhood malignancies. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00005-0] [Reference Citation Analysis]
7 Larson EA, Accardi MV, Zhong Y, Paquette D, Authier S. Drug-Induced Seizures: Considerations for Underlying Molecular Mechanisms. Int J Toxicol 2021;40:403-12. [PMID: 34514888 DOI: 10.1177/10915818211040483] [Reference Citation Analysis]
8 Zhang Y, Chen Y, Wan Y, Zhao Y, Wen Q, Tang X, Shen J, Wu X, Li M, Li X, Li J, Li W, Xiao Z, Du F. Circular RNAs in the Regulation of Oxidative Stress. Front Pharmacol 2021;12:697903. [PMID: 34385919 DOI: 10.3389/fphar.2021.697903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Shulpekova YO, Ablaev VU, Damulin IV. Neurological presentations of inflammatory bowel diseases. Medicinskij alfavit 2021. [DOI: 10.33667/2078-5631-2021-3-34-42] [Reference Citation Analysis]
10 Meena P, Bhargava V, Rana D, Bhalla A, Gupta A. An Approach to Neurological Disorders in a Kidney Transplant Recipient. Kidney360 2020;1:837-44. [PMID: 35372958 DOI: 10.34067/KID.0002052020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Pflugrad H, Nösel P, Ding X, Schmitz B, Lanfermann H, Barg-Hock H, Klempnauer J, Schiffer M, Weissenborn K. Brain function and metabolism in patients with long-term tacrolimus therapy after kidney transplantation in comparison to patients after liver transplantation. PLoS One 2020;15:e0229759. [PMID: 32155172 DOI: 10.1371/journal.pone.0229759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Ronan PJ, Flynn SA, Beresford TP. Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders. Prog Mol Biol Transl Sci 2019;167:125-42. [PMID: 31601401 DOI: 10.1016/bs.pmbts.2019.06.008] [Reference Citation Analysis]
13 See Hoe LE, Bartnikowski N, Wells MA, Suen JY, Fraser JF. Hurdles to Cardioprotection in the Critically Ill. Int J Mol Sci 2019;20:E3823. [PMID: 31387264 DOI: 10.3390/ijms20153823] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang W, Egashira N, Masuda S. Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities. Int J Mol Sci 2019;20:E3210. [PMID: 31261959 DOI: 10.3390/ijms20133210] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
15 Mlejnek P, Frydrych I, Doležel P. Cyclosporin a Potentiates the Cytotoxic Effects of Methyl Methanesulphonate in HL-60 and K562 Cells. Altern Lab Anim 2007;35:79-85. [DOI: 10.1177/026119290703500117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Forsse A, Nielsen TH, Nygaard KH, Nordström CH, Gramsbergen JB, Poulsen FR. Cyclosporin A ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia. Sci Rep 2019;9:3702. [PMID: 30842488 DOI: 10.1038/s41598-019-40245-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
17 Finsterer J. Pathogenicity of the m.1630A > G variant remains elusive if related mutation carriers with similar heteroplasmy rates are asymptomatic. Mol Genet Metab Rep 2019;19:100461. [PMID: 30809469 DOI: 10.1016/j.ymgmr.2019.100461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Mizuma A, Kim JY, Kacimi R, Stauderman K, Dunn M, Hebbar S, Yenari MA. Microglial Calcium Release-Activated Calcium Channel Inhibition Improves Outcome from Experimental Traumatic Brain Injury and Microglia-Induced Neuronal Death. J Neurotrauma 2019;36:996-1007. [PMID: 30351197 DOI: 10.1089/neu.2018.5856] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
19 Ameres M, Melter M, Zant R, Schilling S, Geis T. Liver transplantation during infancy: No increased rate of neurological complications. Pediatr Transplant 2018;22:e13304. [PMID: 30315619 DOI: 10.1111/petr.13304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
21 García M, Haro-Gonzalez JL, Aguirre C. Ciclosporin and chorea: a new association? J Neurol 2018;265:2743-4. [PMID: 30218177 DOI: 10.1007/s00415-018-9055-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 El-yazbi AF, Eid AH, El-mas MM. Cardiovascular and renal interactions between cyclosporine and NSAIDs: Underlying mechanisms and clinical relevance. Pharmacological Research 2018;129:251-61. [DOI: 10.1016/j.phrs.2017.11.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
23 Miklavčič P, Avčin S, Jazbec J, Vipotnik Vesnaver T, Todorova B, Trošt M, Kojović M. Cyclosporine A induced dystonia-parkinsonism. J Neurol Sci 2017;375:68-70. [PMID: 28320190 DOI: 10.1016/j.jns.2017.01.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lückemann L, Unteroberdörster M, Kirchhof J, Schedlowski M, Hadamitzky M. Applications and limitations of behaviorally conditioned immunopharmacological responses. Neurobiol Learn Mem 2017;142:91-8. [PMID: 28216206 DOI: 10.1016/j.nlm.2017.02.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
25 Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
26 Toledano M, Fugate JE. Posterior reversible encephalopathy in the intensive care unit. Handb Clin Neurol 2017;141:467-83. [PMID: 28190431 DOI: 10.1016/B978-0-444-63599-0.00026-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Czaja AJ. Autoimmune Liver Diseases: Autoimmune Hepatitis. Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_15] [Reference Citation Analysis]
28 Korolczuk A, Caban K, Amarowicz M, Czechowska G, Irla-Miduch J. Oxidative Stress and Liver Morphology in Experimental Cyclosporine A-Induced Hepatotoxicity. Biomed Res Int 2016;2016:5823271. [PMID: 27298826 DOI: 10.1155/2016/5823271] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
29 Brodsky MC. The Apparently Blind Infant. Pediatric Neuro-Ophthalmology 2016. [DOI: 10.1007/978-1-4939-3384-6_1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Chen S, Hu J, Xu L, Brandon D, Yu J, Zhang J. Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review. Mol Neurobiol 2016;53:6897-909. [PMID: 26666662 DOI: 10.1007/s12035-015-9560-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
31 Bellwon P, Culot M, Wilmes A, Schmidt T, Zurich M, Schultz L, Schmal O, Gramowski-voss A, Weiss D, Jennings P, Bal-price A, Testai E, Dekant W. Cyclosporine A kinetics in brain cell cultures and its potential of crossing the blood–brain barrier. Toxicology in Vitro 2015;30:166-75. [DOI: 10.1016/j.tiv.2015.01.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
32 Mour G, Wu C. Neurologic Complications After Kidney Transplantation. Seminars in Nephrology 2015;35:323-34. [DOI: 10.1016/j.semnephrol.2015.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
33 Chen LW, Chen JS, Tu YF, Wang ST, Wang LW, Tsai YS, Huang CC. Age-dependent vulnerability of cyclosporine-associated encephalopathy in children. Eur J Paediatr Neurol 2015;19:464-71. [PMID: 25769225 DOI: 10.1016/j.ejpn.2015.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
34 Annaloro C, Costa A, Fracchiolla NS, Mometto G, Artuso S, Saporiti G, Tagliaferri E, Grifoni F, Onida F, Cortelezzi A. Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report. Clin Case Rep 2015;3:650-5. [PMID: 26273463 DOI: 10.1002/ccr3.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
35 Handreck A, Mall EM, Elger DA, Gey L, Gernert M. Different preparations, doses, and treatment regimens of cyclosporine A cause adverse effects but no robust changes in seizure thresholds in rats. Epilepsy Research 2015;112:1-17. [DOI: 10.1016/j.eplepsyres.2015.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
36 Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation- related but different. Expert Opin Drug Saf. 2015;14:1055-1070. [PMID: 25912929 DOI: 10.1517/14740338.2015.1040388] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 11.8] [Reference Citation Analysis]
37 Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol 2015;9:327-33. [PMID: 25160857 DOI: 10.1586/17474124.2014.953060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
38 Shah S, Ginat DT. Calcineurin Inhibitors. Neuroimaging Pharmacopoeia 2015. [DOI: 10.1007/978-3-319-12715-6_23] [Reference Citation Analysis]
39 Orpin S, Ilyas SU. A potentially rare and serious consequence of ciclosporin therapy for psoriasis. Clin Exp Dermatol 2014;39:947-8. [DOI: 10.1111/ced.12451] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
40 Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
41 Day A, Abramson AK, Patel M, Warren RB, Menter MA. The spectrum of oculocutaneous disease. Journal of the American Academy of Dermatology 2014;70:821.e1-821.e19. [DOI: 10.1016/j.jaad.2013.12.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
42 Gera DN, Patil SB, Iyer A, Kute VB, Gandhi S, Kumar D, Trivedi HL. Posterior reversible encephalopathy syndrome in children with kidney disease. Indian J Nephrol 2014;24:28-34. [PMID: 24574628 DOI: 10.4103/0971-4065.125053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
43 Perotti M, Costa L. Cardiac Drugs. Encyclopedia of the Neurological Sciences 2014. [DOI: 10.1016/b978-0-12-385157-4.00254-2] [Reference Citation Analysis]
44 Bae SH, Lee HS, Kang MS, Strupp BJ, Chopp M, Moon J. The levels of pro-inflammatory factors are significantly decreased in cerebral palsy patients following an allogeneic umbilical cord blood cell transplant. Int J Stem Cells 2012;5:31-8. [PMID: 24298353 DOI: 10.15283/ijsc.2012.5.1.31] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
45 Skardelly M, Glien A, Groba C, Schlichting N, Kamprad M, Meixensberger J, Milosevic J. The influence of immunosuppressive drugs on neural stem/progenitor cell fate in vitro. Exp Cell Res 2013;319:3170-81. [PMID: 24001738 DOI: 10.1016/j.yexcr.2013.08.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
46 Sontag CJ, Nguyen HX, Kamei N, Uchida N, Anderson AJ, Cummings BJ. Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury. Stem Cells Transl Med 2013;2:731-44. [PMID: 23981724 DOI: 10.5966/sctm.2012-0175] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
47 Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013;38:343-64. [PMID: 23808490 DOI: 10.1111/apt.12381] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
48 Korolczuk A, Maciejewski M, Czechowska Md, Phd G, Orzeł-pankowska M. Ultrastructural Examination of Renal Tubular Epithelial Cells and Hepatocytes in the Course of Chronic Cyclosporin A Treatment—A Possible Link to Oxidative Stress. Ultrastructural Pathology 2013;37:332-9. [DOI: 10.3109/01913123.2013.810686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
49 Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. Neurol Clin 2013;31:79-138. [PMID: 23186897 DOI: 10.1016/j.ncl.2012.09.008] [Cited by in Crossref: 108] [Cited by in F6Publishing: 118] [Article Influence: 10.8] [Reference Citation Analysis]
50 Pacheco-López G, Doenlen R, Krügel U, Arnold M, Wirth T, Riether C, Engler A, Niemi MB, Christians U, Engler H, Schedlowski M. Neurobehavioural activation during peripheral immunosuppression. Int J Neuropsychopharmacol 2013;16:137-49. [PMID: 22217400 DOI: 10.1017/S1461145711001799] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
51 Textor LH, Hedrick J. The Lived Experience of Peripheral Neuropathy after Solid Organ Transplant. Prog Transpl 2012;22:271-9. [DOI: 10.7182/pit2012703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
52 Czaja AJ. Drug choices in autoimmune hepatitis: part B--Nonsteroids. Expert Rev Gastroenterol Hepatol 2012;6:617-35. [PMID: 23061712 DOI: 10.1586/egh.12.38] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
53 Cho TH, Aguettaz P, Campuzano O, Charriaut-Marlangue C, Riou A, Berthezène Y, Nighoghossian N, Ovize M, Wiart M, Chauveau F. Pre- and post-treatment with cyclosporine A in a rat model of transient focal cerebral ischaemia with multimodal MRI screening. Int J Stroke 2013;8:669-74. [PMID: 22882746 DOI: 10.1111/j.1747-4949.2012.00849.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
54 Christians U, Schmitz V, Klawitter J, Klawitter J. Proteo-Metabolomic Strategies in the Future of Drug Development. In: Caroli S, Záray G, editors. Analytical Techniques for Clinical Chemistry. Hoboken: John Wiley & Sons, Inc.; 2012. pp. 691-774. [DOI: 10.1002/9781118271858.ch24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
55 Wirth T, Ober K, Prager G, Vogelsang M, Benson S, Witzke O, Kribben A, Engler H, Schedlowski M. Repeated recall of learned immunosuppression: evidence from rats and men. Brain Behav Immun 2011;25:1444-51. [PMID: 21645613 DOI: 10.1016/j.bbi.2011.05.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
56 Yi H, Kim SH, Park HG, Yu HS, Kim YS. The effect of systemic injection of cyclosporin A on the phosphorylation of the PKC substrates MARCKS and GAP43 in the rat hippocampus. Neuroscience Letters 2011;497:17-21. [DOI: 10.1016/j.neulet.2011.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
57 Osman MM, Lulic D, Glover L, Stahl CE, Lau T, van Loveren H, Borlongan CV. Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application. Neuropeptides. 2011;45:359-368. [PMID: 21592568 DOI: 10.1016/j.npep.2011.04.002] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
58 Lulic D, Burns J, Bae EC, van Loveren H, Borlongan CV. A Review of Laboratory and Clinical Data Supporting the Safety and Efficacy of Cyclosporin A in Traumatic Brain Injury. Neurosurgery 2011;68:1172-86. [DOI: 10.1227/neu.0b013e31820c6cdc] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
59 Yager JR, Magnotta VA, Mills JA, Vik SM, Weckmann MT, Capizzano AA, Gingrich R, Beglinger LJ. Proton Magnetic Resonance Spectroscopy in adult cancer patients with delirium. Psychiatry Res 2011;191:128-32. [PMID: 21227658 DOI: 10.1016/j.pscychresns.2010.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
60 Wu W, Dnyanmote AV, Nigam SK. Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol Pharmacol. 2011;79:795-805. [PMID: 21325265 DOI: 10.1124/mol.110.070607] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 7.4] [Reference Citation Analysis]
61 Wolf R, Lipozenčić J, Davidovici BB. SEVERE, ACUTE COMPLICATIONS OF DERMATOLOGIC THERAPIES. Emergency Dermatology 2011. [DOI: 10.1017/cbo9780511778339.018] [Reference Citation Analysis]
62 Kuglstatter A, Mueller F, Kusznir E, Gsell B, Stihle M, Thoma R, Benz J, Aspeslet L, Freitag D, Hennig M. Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr D Biol Crystallogr. 2011;67:119-123. [PMID: 21245533 DOI: 10.1107/s0907444910051905] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
63 Feng X, Li J, Liu J, Jin M, Liu X, Du H, Zhang L, Sun Z, Li X. Protective Effect of FK506 on Myocardial Ischemia/Reperfusion Injury by Suppression of CaN and ASK1 Signaling Circuitry. Cardiovasc Toxicol 2011;11:18-27. [DOI: 10.1007/s12012-010-9095-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
64 Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology. 2011;32:50-57. [PMID: 21075140 DOI: 10.1016/j.neuro.2010.10.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
65 Martinez-Palli G, Hirose R, Liu T, Xu F, Dang K, Feiner J, Serkova NJ, Niemann CU. Donor pre-treatment with everolimus or cyclosporine does not reduce ischaemia-reperfusion injury in a rat kidney transplant model. Nephrol Dial Transplant 2011;26:1813-20. [PMID: 21068143 DOI: 10.1093/ndt/gfq646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
66 Illsinger S, Janzen N, Lücke T, Bednarczyk J, Schmidt KH, Hoy L, Sander J, Das AM. Cyclosporine A: impact on mitochondrial function in endothelial cells. Clin Transplant 2011;25:584-93. [PMID: 20633034 DOI: 10.1111/j.1399-0012.2010.01301.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
67 Böhmer AE, Brum LM, Souza DG, Corrêa AM, Oses JP, Viola GG, Saraiva PJ, Driemeier D, Portela LV, Souza DO. Chronic treatment with cyclosporine affects systemic purinergic parameters, homocysteine levels and vascular disturbances in rats. Chem Biol Interact 2010;188:15-20. [PMID: 20599430 DOI: 10.1016/j.cbi.2010.06.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
68 Klawitter J, Gottschalk S, Hainz C, Leibfritz D, Christians U, Serkova NJ. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol 2010;23:608-19. [PMID: 20148532 DOI: 10.1021/tx900351q] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
69 Braakman HM, Lodder J, Postma AA, Span LF, Mess WH. Vasospasm is a significant factor in cyclosporine-induced neurotoxicity: case report. BMC Neurol 2010;10:30. [PMID: 20459819 DOI: 10.1186/1471-2377-10-30] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
70 Nulman I, Sgro M, Barrera M, Chitayat D, Cairney J, Koren G. Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant. Paediatr Drugs 2010;12:113-22. [PMID: 20095652 DOI: 10.2165/11316280-000000000-00000] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
71 Böhmer AE, Souza DG, Hansel G, Brum LM, Portela LV, Souza DO. Long-term cyclosporine treatment in non-transplanted rats and metabolic risk factors of vascular diseases. Chemico-Biological Interactions 2010;185:53-8. [DOI: 10.1016/j.cbi.2010.02.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
72 Sharief U, Perry DJ. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 2009;8:163-5. [PMID: 19632931 DOI: 10.3816/CCC.2009.n.026] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
73 Frydrych I, Mlejnek P, Dolezel P. Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression. Toxicol In Vitro 2009;23:1482-90. [PMID: 19735720 DOI: 10.1016/j.tiv.2009.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
74 Dzudie A, Boissonnat P, Roussoulieres A, Cakmak, Mosbah K, Bejui FT, Obadia JF, Sebbag L. Cyclosporine-related posterior reversible encephalopathy syndrome after heart transplantation: should we withdraw or reduce cyclosporine?: case reports. Transplant Proc 2009;41:716-20. [PMID: 19328965 DOI: 10.1016/j.transproceed.2009.01.041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
75 Hooshmand MJ, Sontag CJ, Uchida N, Tamaki S, Anderson AJ, Cummings BJ. Analysis of host-mediated repair mechanisms after human CNS-stem cell transplantation for spinal cord injury: correlation of engraftment with recovery. PLoS One. 2009;4:e5871. [PMID: 19517014 DOI: 10.1371/journal.pone.0005871] [Cited by in Crossref: 83] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
76 Fukunaga K, Nagase K, Kusaka T, Hida N, Ohda Y, Yoshida K, Tozawa K, Kamikozuru K, Iimuro M, Nakamura S, Miwa H, Matsumoto T. Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study. Gut Liver 2009;3:41-7. [PMID: 20479900 DOI: 10.5009/gnl.2009.3.1.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
77 Al-araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. The Lancet Neurology 2009;8:192-204. [DOI: 10.1016/s1474-4422(09)70015-8] [Cited by in Crossref: 314] [Cited by in F6Publishing: 333] [Article Influence: 22.4] [Reference Citation Analysis]
78 Kim JW, Moon JM, Kang E, Choi YJ, Kim JS, Choi JG, Seo HY, Sung HJ, Choi CW, Kim BS, Kim JS, Seo W. Reversible Posterior Leukoencephalopathy Syndrome in a Patient with Relapsed Hodgkin's Disease: A Case Report. Korean J Hematol 2009;44:177. [DOI: 10.5045/kjh.2009.44.3.177] [Reference Citation Analysis]
79 Leon C, Jia J, Qiu G, Hill JS, Wasan KM. Modifications in low-density lipoprotein receptor expression affects Cyclosporin A cellular uptake and cytotoxicity. J Pharm Sci 2008;97:2350-61. [PMID: 17823952 DOI: 10.1002/jps.21141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
80 Cunningham MA, Austin BA, Li Z, Liu B, Yeh S, Chan CC, Anglade E, Velagaleti P, Nussenblatt RB. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. Invest Ophthalmol Vis Sci 2009;50:249-55. [PMID: 18708627 DOI: 10.1167/iovs.08-1891] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
81 Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur J Gastroenterol Hepatol 2008;20:596-600. [PMID: 18679059 DOI: 10.1097/MEG.0b013e3282f5e9f3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
82 Dineen R, Sibtain N, Karani J, Lenthall R. Cerebral manifestations in liver disease and transplantation. Clinical Radiology 2008;63:586-99. [DOI: 10.1016/j.crad.2007.08.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
83 Shah-khan FM, Pinedo D, Shah P. Reversible posterior leukoencephalopathy syndrome and anti-neoplastic agents: a review. Oncol Rev 2007;1:152-61. [DOI: 10.1007/s12156-007-0018-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
84 Niemann CU, Serkova NJ. Biochemical mechanisms of nephrotoxicity: application for metabolomics. Expert Opinion on Drug Metabolism & Toxicology 2007;3:527-44. [DOI: 10.1517/17425255.3.4.527] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
85 Dohgu S, Nishioku T, Sumi N, Takata F, Nakagawa S, Naito M, Tsuruo T, Yamauchi A, Shuto H, Kataoka Y. Adverse effect of cyclosporin A on barrier functions of cerebral microvascular endothelial cells after hypoxia-reoxygenation damage in vitro. Cell Mol Neurobiol 2007;27:889-99. [PMID: 17934807 DOI: 10.1007/s10571-007-9209-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
86 Ravikumar R, Mcewen ML, Springer JE. Post-Treatment with the Cyclosporin Derivative, NIM811, Reduced Indices of Cell Death and Increased the Volume of Spared Tissue in the Acute Period following Spinal Cord Contusion. Journal of Neurotrauma 2007;24:1618-30. [DOI: 10.1089/neu.2007.0329] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
87 Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 2007;21:483-502. [PMID: 17521228 DOI: 10.2165/00023210-200721060-00005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
88 Mcewen ML, Sullivan PG, Springer JE. Pretreatment with the Cyclosporin Derivative, NIM811, Improves the Function of Synaptic Mitochondria following Spinal Cord Contusion in Rats. Journal of Neurotrauma 2007;24:613-24. [DOI: 10.1089/neu.2006.9969] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 3.3] [Reference Citation Analysis]
89 Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry 2007;78:342-9. [PMID: 17369589 DOI: 10.1136/jnnp.2006.106211] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
90 Erbetta A, Lauria G, Sghirlanzoni A. Complicazioni della chemioterapia. Le complicazioni neurologiche in oncologia. [DOI: 10.1007/978-88-470-0440-5_12] [Reference Citation Analysis]
91 Kieseier BC, Wiendl H, Hartung HP. The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 2006;19:433-6. [PMID: 16969151 DOI: 10.1097/01.wco.0000245364.51823.3b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
92 Grimm S, Brdiczka D. The permeability transition pore in cell death. Apoptosis 2007;12:841-55. [DOI: 10.1007/s10495-007-0747-3] [Cited by in Crossref: 137] [Cited by in F6Publishing: 142] [Article Influence: 8.6] [Reference Citation Analysis]
93 Takadera T, Ohyashiki T. Caspase-dependent apoptosis induced by calcineurin inhibitors was prevented by glycogen synthase kinase-3 inhibitors in cultured rat cortical cells. Brain Research 2007;1133:20-6. [DOI: 10.1016/j.brainres.2006.11.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
94 Mielke S, Potthoff K, Feuerhake F, Bley TA, Windfuhr M, Bertz H, Finke J. Fatal Leukoencephalopathy after Reduced-Intensity Allogeneic Stem Cell Transplantation. Oncol Res Treat 2007;30:49-52. [DOI: 10.1159/000098229] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Wiendl H, Hohlfeld R. Review of Novel Immunotherapeutic Strategies for MS. Immune Regulation and Immunotherapy in Autoimmune Disease 2007. [DOI: 10.1007/978-0-387-36003-4_14] [Reference Citation Analysis]
96 Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
97 Fontenay M, Cathelin S, Amiot M, Gyan E, Solary E. Mitochondria in hematopoiesis and hematological diseases. Oncogene 2006;25:4757-67. [PMID: 16892088 DOI: 10.1038/sj.onc.1209606] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 3.6] [Reference Citation Analysis]
98 Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005;1:629-40. [PMID: 16863429 DOI: 10.1517/17425255.1.4.629] [Cited by in Crossref: 118] [Cited by in F6Publishing: 121] [Article Influence: 6.9] [Reference Citation Analysis]
99 Fusar-poli P, Picchioni M, Martinelli V, Bhattacharyya S, Cortesi M, Barale F, Politi P. Anti-depressive Therapies After Heart Transplantation. The Journal of Heart and Lung Transplantation 2006;25:785-93. [DOI: 10.1016/j.healun.2006.03.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
100 Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005;27:733-7. [PMID: 16404806 DOI: 10.1097/01.ftd.0000179846.30342.65] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
101 Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
102 Chegounchi M, Hanna MG, Neild GH. Progressive neurological disease induced by tacrolimus in a renal transplant recipient: case presentation. BMC Nephrol 2006;7:7. [PMID: 16573841 DOI: 10.1186/1471-2369-7-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
103 Erxleben C, Liao Y, Gentile S, Chin D, Gomez-Alegria C, Mori Y, Birnbaumer L, Armstrong DL. Cyclosporin and Timothy syndrome increase mode 2 gating of CaV1.2 calcium channels through aberrant phosphorylation of S6 helices. Proc Natl Acad Sci U S A 2006;103:3932-7. [PMID: 16537462 DOI: 10.1073/pnas.0511322103] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 5.2] [Reference Citation Analysis]
104 Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171-184. [PMID: 15892107 DOI: 10.1002/jca.20046] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
105 Bouchier-Hayes L, Lartigue L, Newmeyer DD. Mitochondria: pharmacological manipulation of cell death. J Clin Invest 2005;115:2640-7. [PMID: 16200197 DOI: 10.1172/JCI26274] [Cited by in Crossref: 142] [Cited by in F6Publishing: 149] [Article Influence: 7.9] [Reference Citation Analysis]
106 Christians U, Reisdorph N, Klawitter J, Schmitz V. Biomarkers of immunosuppressive drug toxicity: . Current Opinion in Organ Transplantation 2005;10:284-94. [DOI: 10.1097/01.mot.0000184018.31573.34] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
107 Dietemann JL, Botelho C, Nogueira T, Vargas MI, Audibert C, Abu Eid M, Bogorin A, Bernardo R, Jacques C, Kremer S, Zöllner G. [Imaging in acute toxic encephalopathy]. J Neuroradiol 2004;31:313-26. [PMID: 15545943 DOI: 10.1016/s0150-9861(04)97010-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]